
Janux and Bristol Myers Squibb partner on tumour-activated therapeutic
Bristol Myers Squibb and immunotherapy developer Janux Therapeutics have announced a collaboration and exclusive worldwide license agreement. Under the terms of the agreement, the companies will develop an undisclosed, novel, tumour-activated therapeutic targeting a validated solid tumour antigen expressed across several human cancer types. Janux may receive up to $50… Read More
